Northland says MiMedx ‘oversold,’ sees ‘compelling buying opportunity’

Northland argues that MiMedx (MDXG) shares are “oversold” and considers the current valuation “a compelling buying opportunity” as the firm believes the current share price does not reflect improving fundamentals and upside from potential implementation of pending LCDs. The firm maintains its Outperform rating and $12 price target on MiMedx shares.